Get the Stockscreener App
2.0422
0.27%
0.0172
Pds Biotechnology Corporation stock is traded at $2.0422, with a volume of 10,527.
It is up +0.27% in the last 24 hours and down -34.92% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$2.025
Open:
$2.02
24h Volume:
10,527
Relative Volume:
0.03
Market Cap:
$73.82M
Revenue:
-
Net Income/Loss:
$-42.94M
P/E Ratio:
-1.2606
EPS:
-1.62
Net Cash Flow:
$-33.64M
1W Performance:
-9.76%
1M Performance:
-34.92%
6M Performance:
-42.96%
1Y Performance:
-67.62%
1-Day Range:
$2.02
$2.05
1-Week Range:
$1.90
$2.23
52-Week Range:
$1.53
$6.68
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| PDSB | 2.04 | 73.82M | 0 | -42.94M | -33.64M | -1.62 |
| VRTX | 447.53 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.03 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.31 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround - Yahoo Finance
PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World
PDS Biotechnology's (PDSB) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference - StockTitan
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Call Transcript - Insider Monkey
PDS Biotechnology Corporation (PDSB) Quarterly 10-Q Report - Quartzy
PDS Biotechnology: Q3 Earnings Snapshot - New Haven Register
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... By GuruFocus - Investing.com Canada
PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks
Earnings call: PDS Biotech reports progress in HPV cancer trials By Investing.com - Investing.com Canada
PDSB stock touches 52-week low at $2.21 amid market challenges - Investing.com India
PDS Biotechnology Shares Down 18% After Phase 3 Trial Modifications - MarketWatch
PDS Biotechnology Corporation Provides Clinical Programs Update - Marketscreener.com
U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results - The Manila Times
PDS Biotech Reports $10.7M Q3 Loss, Streamlines Phase 3 Trial Design | PDSB Stock News - StockTitan
PDS Biotechnology (PDSB) to Release Earnings on Thursday - Defense World
PDS Biotechnology (NASDAQ:PDSB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
PDS Biotechnology (PDSB) Set to Announce Quarterly Earnings on Thursday - MarketBeat
PDS Biotech: Interview With President And CEO Frank Bedu-Addo About The Immunotherapy Company - Pulse 2.0
PDS Biotechnology Sets Q3 Earnings Call: Clinical Updates Expected Nov 14 | PDSB Stock News - StockTitan
Contrasting Semiconductor Manufacturing International (OTCMKTS:SMICY) & POET Technologies (NASDAQ:POET) - Defense World
StockNews.com Initiates Coverage on Ark Restaurants (NASDAQ:ARKR) - Defense World
Jones Soda Announces Departure of President and CEO, David Knight, and Appointment of Interim CEO, Paul Norman - Defense World
Mastech Digital (NYSE:MHH) Coverage Initiated by Analysts at StockNews.com - Defense World
PDS Biotechnology Co. (NASDAQ:PDSB) Receives $14.25 Consensus Price Target from Analysts - MarketBeat
Head-To-Head Analysis: Edison International (NYSE:EIX) and AltC Acquisition (NYSE:ALCC) - Defense World
FS KKR Capital Corp. (NYSE:FSK) Given Consensus Rating of “Hold” by Brokerages - Defense World
StockNews.com Begins Coverage on TRX Gold (NYSE:TRX) - Defense World
Mastech Digital (NYSE:MHH) Now Covered by Analysts at StockNews.com - Defense World
Bowhead Specialty (NYSE:BOW) versus Horace Mann Educators (NYSE:HMN) Critical Survey - Defense World
Zacks Research Issues Negative Estimate for CSX Earnings - Defense World
Hillman Solutions (HLMN) to Announce Quarterly Earnings on Tuesday - Defense World
Evolv Technology Holdings CEO terminated, replaced by Michael Ellenbogen as Interim CEO - Defense World
Chase (NYSE:CCF) Now Covered by Analysts at StockNews.com - Defense World
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Upgraded by StockNews.com - MarketBeat
HC Wainwright Reaffirms Buy Rating for PDS Biotechnology (NASDAQ:PDSB) - MarketBeat
Is There More Room To Run For This Immunotherapy Company Stock After Hitting New High? - RTTNews
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine - The Manila Times
Critical Review: PDS Biotechnology (NASDAQ:PDSB) & InflaRx (NASDAQ:IFRX) - Defense World
NY Biopharma Shares Promising Clinical Data - Streetwise Reports
Data Readouts At ASCO (MRUS, ORIC, CGEN, PDSB...) - RTTNews
H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. - Streetwise Reports
PDS Biotechnology Co. (NASDAQ:PDSB) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Size, Spotlight on Future Potentials (2024-2034) - IndiaPolitics.com
CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight - The Malaysian Reserve
Mass. Biotech Receives FDA Approval - Streetwise Reports
PDS Biotechnology Corporation: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):